Positions

Selected Publications

Academic Article

Year Title Altmetric
2021 Alternative strategies of posttransplant influenza vaccination in adult solid organ transplant recipientsAmerican Journal of Transplantation.  21:938-949. 2021
2021 Corrigendum to: Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE TrialJournal of Infectious Diseases.  223:352. 2021
2021 One-year statin persistence and adherence in adults with HIV in the United StatesJournal of Clinical Lipidology.  15:181-191. 2021
2020 Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials 2020
2020 Hepatitis C among high-risk alabamians: Disease burden and screening effectivenessJournal of Infectious Diseases.  222:S365-S375. 2020
2020 An evaluation of baseline kidney function in the REPRIEVE trial of pitavastatin in human immunodeficiency virusJournal of Infectious Diseases.  222:S41-S51. 2020
2020 Patterns of antiretroviral therapy use and immunologic profiles at enrollment in the REPRIEVE trialJournal of Infectious Diseases.  222:S8-S19. 2020
2020 Physical function impairment and frailty in middle-aged people living with human immunodeficiency virus in the REPRIEVE trial ancillary study PREPAREJournal of Infectious Diseases.  222:S52-S62. 2020
2020 Immune Activation and Inflammation in People with Human Immunodeficiency Virus: Challenging TargetsJournal of Infectious Diseases.  221:1567-1570. 2020
2020 Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infectionNew England Journal of Medicine.  382:1124-1135. 2020
2020 Physical activity trends and metabolic health outcomes in people living with HIV in the US, 2008–2015Progress in Cardiovascular Diseases.  63:170-177. 2020
2020 Sexually transmitted infections and sexual behaviors of men who have sex with men in an American Deep South PrEP clinicInternational Journal of STD and AIDS.  31:127-135. 2020
2020 Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: critical role of central coordination 2020
2020 Direct acting antivirals in hepatitis c-infected kidney transplant recipients: Associations with long-term graft failure and patient mortalityPathogens and Immunity.  5:275-290. 2020
2020 Obesity Affects the Association of Bioelectrical Impedance Phase Angle With Mortality in People Living With HIVJournal of the Association of Nurses in AIDS Care.  31:51-59. 2020
2019 Brief Report: Aging Attenuates the Association between Coronary Artery Calcification and Bone Loss among HIV-Infected Persons 2019
2019 Rapid boosting of HIV-1 neutralizing antibody responses in humans following a prolonged immunologic rest periodJournal of Infectious Diseases.  219:1755-1765. 2019
2019 Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkersAmerican Heart Journal.  212:1-12. 2019
2019 Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)American Heart Journal.  212:23-35. 2019
2019 Associations of food insecurity and psychosocial measures with diet quality in adults aging with HIV 2019
2019 Vitamin D does not modulate immune-mediated bone loss during ART initiationAntiviral Therapy.  24:355-362. 2019
2018 HIV-1 latent reservoir size and diversity are stable following brief treatment interruptionJournal of Clinical Investigation.  128:3102-3115. 2018
2018 Low-density lipoprotein cholesterol response after statin initiation among persons living with human immunodeficiency virusJournal of Clinical Lipidology.  12:988-998.e5. 2018
2018 Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune statusAIDS.  32:1279-1287. 2018
2018 Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status.AIDS.  32:1279-1287. 2018
2018 The hidden risk: Incorporating inflammation and HIV serostatus into coronary artery disease screeningJournal of Nuclear Cardiology.  25:884-886. 2018
2018 Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trialPLoS ONE.  13. 2018
2018 Reply 2018
2017 The Impact of Statin and Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Therapy on Cognitive Function in Adults with Human Immunodeficiency Virus InfectionClinical Infectious Diseases.  65:2042-2049. 2017
2017 Genome-wide admixture and association study of subclinical atherosclerosis in the Women’s Interagency HIV Study (WIHS)PLoS ONE.  12. 2017
2017 Reproductive Aging and Hepatic Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected WomenClinical Infectious Diseases.  65:1695-1702. 2017
2017 Racial differences in calculated bioavailable Vitamin D with Vitamin D/calcium supplementationAIDS.  31:2337-2344. 2017
2017 Examining Sexual Function among Individuals with HIV in a Midwestern US Urban Outpatient Clinic SettingJournal of the International Association of Providers of AIDS Care.  16:481-486. 2017
2017 The Relationship of Social Support and Neighborhood Perceptions among Individuals with HIVJournal of the International Association of Providers of AIDS Care.  16:440-445. 2017
2017 Monocyte bioenergetic function is associated with body composition in virologically suppressed HIV-infected womenRedox Biology.  12:648-656. 2017
2017 Race and sex differences in ambulatory blood pressure measures among HIV+ adultsJournal of the American Society of Hypertension.  11:420-427.e3. 2017
2017 Vitamin D deficiency is associated with IL-6 levels and monocyte activation in HIV-infected personsPLoS ONE.  12. 2017
2017 Local Ancestry and Clinical Cardiovascular Events Among African Americans From the Atherosclerosis Risk in Communities Study 2017
2017 Admixture Mapping of Subclinical Atherosclerosis and Subsequent Clinical Events among African Americans in 2 Large Cohort StudiesCirculation: Cardiovascular Genetics.  10. 2017
2017 Brief Report: The Right People, Right Places, and Right Practices: Disparities in PrEP Access among African American Men, Women, and MSM in the Deep South 2017
2017 Dysregulation of Systemic and Mucosal Humoral Responses to Microbial and Food Antigens as a Factor Contributing to Microbial Translocation and Chronic Inflammation in HIV-1 InfectionPLoS Pathogens.  13. 2017
2017 Vitamin D Supplementation Does Not Affect Metabolic Changes Seen with ART InitiationOpen Forum Infectious Diseases.  4. 2017
2016 Duration of Influenza Virus Shedding among HIV-Infected Adults in the cART Era, 2010-2011AIDS Research and Human Retroviruses.  32:1180-1186. 2016
2016 Effect of HIV antibody VRC01 on viral rebound after treatment interruptionNew England Journal of Medicine.  375:2037-2050. 2016
2016 Characterizing failure to establish hepatitis C care of baby boomers diagnosed in the emergency departmentOpen Forum Infectious Diseases.  3. 2016
2016 Metabolic Complications and Glucose Metabolism in HIV Infection: A Review of the EvidenceCurrent HIV/AIDS Reports.  13:289-296. 2016
2016 Effects of pegylated interferon/ribavirin on bone turnover markers in HIV/Hepatitis C virus-coinfected patientsAIDS Research and Human Retroviruses.  32:325-328. 2016
2016 Psychiatric Diagnoses among an HIV-Infected Outpatient Clinic PopulationJournal of the International Association of Providers of AIDS Care.  15:126-130. 2016
2016 Ambulatory blood pressure monitoring in individuals with HIV: A systematic review and meta-analysisPLoS ONE.  11. 2016
2016 Incidence and predictors of abnormal anal cytology findings among HIV-infected adults receiving contemporary antiretroviral therapyJournal of Infectious Diseases.  213:351-360. 2016
2016 Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: Results of an exploratory substudy of METABOLIK, a phase 4, randomized trialHIV Clinical Trials.  17:72-77. 2016
2016 High Prevalence of Low Bone Mineral Density and Substantial Bone Loss over 4 Years among HIV-Infected Persons in the Era of Modern Antiretroviral TherapyAIDS Research and Human Retroviruses.  32:59-67. 2016
2016 Low bone mineral density and risk of incident fracture in HIV-infected adultsAntiviral Therapy.  21:45-54. 2016
2016 Vitamin D and bone loss in HIVCurrent Opinion in HIV and AIDS.  11:277-284. 2016
2015 Mechanisms Influencing Circadian Blood Pressure Patterns Among Individuals with HIVCurrent Hypertension Reports.  17. 2015
2015 Normal T-cell activation in elite controllers with preserved CD4 + T-cell countsAIDS.  29:2245-2254. 2015
2015 Extended-release niacin versus fenofibrate in HIV-infected participants with low high-density lipoprotein cholesterol: Effects on endothelial function, lipoproteins, and inflammationClinical Infectious Diseases.  61:840-849. 2015
2015 Obesity is Associated with Race/Sex Disparities in Diabetes and Hypertension Prevalence, but Not Cardiovascular Disease, among HIV-Infected AdultsAIDS Research and Human Retroviruses.  31:898-904. 2015
2015 Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1New England Journal of Medicine.  373:714-725. 2015
2015 Maternal post-absorptive leucine kinetics during late pregnancy in US women with HIV taking antiretroviral therapy: A cross-sectional pilot studyClinical nutrition ESPEN.  10:e140-e146. 2015
2015 Safety and immunogenicity of modified vaccinia Ankara-Bavarian Nordic smallpox vaccine in vaccinia-naive and experienced human immunodeficiency virus-infected individuals: An open-label, controlled clinical phase II trialOpen Forum Infectious Diseases.  2. 2015
2015 Persistent HIV-related stigma among an outpatient US clinic population.International Journal of STD and AIDS.  26:243-250. 2015
2015 Preliminary outcomes of a pilot physical therapy program for HIV-infected patients with chronic pain 2015
2015 A better screening tool for HIV-associated neurocognitive disorders: Is it what clinicians need?AIDS.  29:895-902. 2015
2015 Impact of poor retention in HIV medical care on hepatitis B vaccinationJournal of the International Association of Providers of AIDS Care.  14:185-190. 2015
2015 Inhibition of the lymphocyte metabolic switch by the oxidative burst of human neutrophilsClinical Science.  129:489-504. 2015
2015 Parks as a tool for HIV managementJournal of the International Association of Providers of AIDS Care.  14:8-11. 2015
2015 Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency departmentHepatology.  61:776-782. 2015
2015 Vitamin D and Calcium attenuate bone loss with antiretroviral therapy initiation: A Randomized TrialAnnals of Internal Medicine.  162:815-824. 2015
2014 National estimates of healthcare utilization by individuals with hepatitis C virus infection in the United StatesClinical Infectious Diseases.  59:755-764. 2014
2014 Improving cervical cancer screening rates in an urban HIV clinic 2014
2014 Bone alterations associated with HIVCurrent HIV/AIDS Reports.  11:233-240. 2014
2014 Depression severity is associated with increased risk behaviors and decreased CD4 cell counts 2014
2014 Factors associated with delayed hepatitis b viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort 2014
2014 Beliefs, experience, and interest in pharmacotherapy among smokers with HIVAmerican Journal of Health Behavior.  38:284-296. 2014
2014 Metabolic consequences of HIV: Pathogenic insightsCurrent HIV/AIDS Reports.  11:35-44. 2014
2014 Bones, fractures, antiretroviral therapy and HIV topical collection on HIV/AIDSCurrent Infectious Disease Reports.  16. 2014
2014 Current practices of screening for incident hepatitis C virus (HCV) infection among HIV-infected, HCV-uninfected individuals in primary careClinical Infectious Diseases.  59:1686-1693. 2014
2014 Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patientsAIDS.  28:2627-2631. 2014
2014 HIV-Related Metabolic Comorbidities in the Current ART EraInfectious Disease Clinics of North America.  28:457-476. 2014
2013 Identifying risk factors for HIV-associated neurocognitive disorders using the international HIV dementia scaleJournal of Neuroimmune Pharmacology.  8:1114-1122. 2013
2013 Are neighborhood conditions associated with HIV management?HIV Medicine.  14:624-632. 2013
2013 Relationships among HIV infection, metabolic risk factors, and left ventricular structure and functionAIDS Research and Human Retroviruses.  29:1151-1160. 2013
2013 Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental deathClinical Infectious Diseases.  56:1471-1479. 2013
2013 Disparities in prevalence of key chronic diseases by gender and race/ethnicity among antiretroviraltreated HIV-infected adults in the USAntiviral Therapy.  18:65-75. 2013
2013 Efavirenz outperforms boosted atazanavir among treatment-naive HIV-1-infected persons in routine clinical careJournal of the International Association of Providers of AIDS Care.  12:138-141. 2013
2013 Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia ankara as a smallpox vaccine in HIV-infected subjectsJournal of Infectious Diseases.  207:749-758. 2013
2013 The Alzheimer's disease-8 and Montreal Cognitive Assessment as screening tools for neurocognitive impairment in HIV-infected personsJournal of NeuroVirology.  19:109-116. 2013
2013 Pain is independently associated with impaired physical function in HIV-infected patientsPain Medicine.  14:1985-1993. 2013
2013 Pilot study of pioglitazone and exercise training effects on basal myocardial substrate metabolism and left ventricular function in hiv-positive individuals with metabolic complicationsHIV Clinical Trials.  14:303-312. 2013
2012 Screening anxiety in the HIV clinicAIDS and Behavior.  16:2407-2413. 2012
2012 Reduced diastolic function and left ventricular mass in HIV-negative preadolescent children exposed to antiretroviral therapy in uteroAIDS.  26:2053-2058. 2012
2012 Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV Type 1-infected subjects over 48 weeksAIDS Research and Human Retroviruses.  28:1184-1195. 2012
2012 18FDG PET-CT imaging detects arterial inflammation and early atherosclerosis in HIV-infected adults with cardiovascular disease risk factorsJournal of inflammation.  9. 2012
2012 Urban farming: A non-traditional intervention for HIV-related distressAIDS and Behavior.  16:1238-1242. 2012
2012 Sometimes, more is betterJournal of Infectious Diseases.  205:697-699. 2012
2012 Transmitted drug-resistant HIV type 1 remains prevalent and impacts virologic outcomes despite genotype-guided antiretroviral therapyAIDS Research and Human Retroviruses.  28:259-264. 2012
2012 Cystatin C and baseline renal function among HIV-infected persons in the SUN studyAIDS Research and Human Retroviruses.  28:148-155. 2012
2012 Reply to Ganesan et alJournal of Infectious Diseases.  205:518-519. 2012
2012 Mental health disorders and the risk of AIDS-defining illness and death in HIV-infected veteransAIDS.  26:229-234. 2012
2012 A Review of Opioid Prescribing Practices and Associations with Repeat Opioid Prescriptions in a Contemporary Outpatient HIV ClinicPain Practice.  12:440-448. 2012
2012 Effect of darunavir on lipid profile in HIV-infected patientsHIV Clinical Trials.  13:256-270. 2012
2012 Serostatus disclosure among adults with HIV in the era of HIV therapyAIDS Patient Care and STDS.  26:29-35. 2012
2011 Effects of human immunodeficiency virus and metabolic complications on myocardial nutrient metabolism, blood flow, and oxygen consumption: a cross-sectional analysisCardiovascular Diabetology.  10. 2011
2011 Performances on the cogstate and standard neuropsychological batteries among HIV patients without dementiaAIDS and Behavior.  15:1902-1909. 2011
2011 Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohortClinical Infectious Diseases.  53:826-835. 2011
2011 A review of premature frailty in HIV-infected persons; another manifestation of HIV-related accelerated agingCurrent Aging Science.  4:33-41. 2011
2011 Increasing clarity on bone loss associated with antiretroviral initiationJournal of Infectious Diseases.  203:1705-1707. 2011
2011 Erratum: High prevalence of echocardiographic abnormalities among HIV-infected persons in the era of highly active antiretroviral therapy (Clinical Infectious Diseases (2011) 52 (378-386))Clinical Infectious Diseases.  52:1200. 2011
2011 Factors associated with non-adherence to antiretroviral therapy in the SUN study 2011
2011 High prevalence of echocardiographic abnormalities among HIV-infected persons in the era of highly active antiretroviral therapyClinical Infectious Diseases.  52:378-386. 2011
2011 Low vitamin D among HIV-infected adults: Prevalence of and risk factors for low vitamin D levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the us general populationClinical Infectious Diseases.  52:396-405. 2011
2011 The rapidly evolving research on vitamin D among HIV-infected populationsCurrent Infectious Disease Reports.  13:83-93. 2011
2011 Alcohol consumption is associated with poor health in HIV clinic patient population: A behavioral surveillance studyAIDS and Behavior.  15:209-213. 2011
2011 Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity 2011
2011 GM-CSF Fails to Improve Immune Responses to Booster Hepatitis B Vaccination in HIV-Infected Individuals.Open Virology Journal.  5:109-113. 2011
2011 Perceptions of alcohol risk among individuals living with HIV 2011
2010 Factors associated with prevalent abnormal anal cytology in a large cohort of HIV-infected adults in the United StatesJournal of Infectious Diseases.  202:1567-1576. 2010
2010 Bone disease in HIV infection: A practical review and recommendations for HIV care providersClinical Infectious Diseases.  51:937-946. 2010
2010 Do brief screening questions or provider perception accurately identify persons with low health literacy in the HIV primary care setting?AIDS Patient Care and STDS.  24:623-629. 2010
2010 Differences and changes in human papillomavirus type 16 variant status in human immunodeficiency virus-positive adults are not uncommonJournal of General Virology.  91:2068-2072. 2010
2010 Yoga lifestyle intervention reduces blood pressure in HIV-infected adults with cardiovascular disease risk factorsHIV Medicine.  11:379-388. 2010
2010 Comparisons of sexual behaviors and STD prevalence among older and younger individuals with HIV infection 2010
2010 The interplay of sociodemographic factors on virologic suppression among a U.S. outpatient HIV clinic populationAIDS Patient Care and STDS.  24:229-235. 2010
2010 Sexual behaviors and results of bacterial sexually transmitted infections testing among frail HIV-infected individualsJournal of the International Association of Physicians in AIDS Care.  9:30-33. 2010
2010 Aging and HIV infection: A comparison between older HIV-infected persons and the general populationHIV Clinical Trials.  11:100-109. 2010
2010 Renal and Urologic Emergencies in the HIV-infected PatientEmergency Medicine Clinics of North America.  28:343-354. 2010
2010 The effect of acid reduction with a proton pump inhibitor on the pharmacokinetics of lopinavir or ritonavir in HIV-infected patients on lopinavir/ritonavir-based therapy.Journal of Clinical Pharmacology.  50:1050-1055. 2010
2009 A review of nucleoside reverse transcriptase inhibitor use to prevent perinatal transmission of HIVExpert Opinion on Drug Safety.  8:683-694. 2009
2009 Frailty among HIV-infected persons in an urban outpatient care settingJournal of Infection.  59:346-352. 2009
2009 Routine screening for depression: Identifying a challenge for successful HIV careAIDS Patient Care and STDS.  23:949-955. 2009
2009 Can you hear me now? Limited use of technology among an urban HIV-infected cohort 2009
2009 Sub-optimal CD4 recovery on long-term suppressive highly active antiretroviral therapy is associated with favourable outcomeHIV Medicine.  10:439-446. 2009
2009 Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapyHIV Medicine.  10:343-350. 2009
2009 The study to understand the natural history of HIV and AIDS in the Era of effective therapy (SUN study)American Journal of Epidemiology.  169:642-652. 2009
2009 HIV and aging: two converging epidemics.Missouri Medicine.  106:269-273. 2009
2008 Adverse effects of tenofovir use in HIV-infected pregnant women and their infantsAnnals of Pharmacotherapy.  42:1581-1585. 2008
2008 Effect of postpartum HIV treatment discontinuation on long-term maternal outcomeJournal of the International Association of Physicians in AIDS Care.  7:245-251. 2008
2008 Incidence of sexually transmitted infections among HIV-infected women using depot medroxyprogesterone acetate contraceptionContraception.  78:125-130. 2008
2008 The aging of the HIV epidemicCurrent HIV/AIDS Reports.  5:150-158. 2008
2008 Regional adipose tissue and elevations in serum aminotransferases in HIV-infected individuals 2008
2007 An overview of vaccinations in HIVCurrent HIV/AIDS Reports.  4:105-113. 2007
2007 Association between hepatitis C virus coinfection and regional adipose tissue volume in HIV-infected men and women 2007
2007 FcRL6, a new ITIM-bearing receptor on cytolytic cells, is broadly expressed by lymphocytes following HIV-1 infectionBlood.  109:3786-3793. 2007
2007 Safety and tolerability of sequential pegylated IFN-α2a and tenofovir for hepatitis B infection in HIV+ individualsHIV Clinical Trials.  8:173-181. 2007
2007 Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient populationClinical Infectious Diseases.  44:726-734. 2007
2007 Predictors of immunity after hepatitis a vaccination in HIV-infected personsJournal of Viral Hepatitis.  14:189-193. 2007
2007 Factors associated with seronegative chronic hepatitis C virus infection in HIV infectionClinical Infectious Diseases.  44:577-583. 2007
2006 Patterns of primary antiretroviral drug resistance in antiretroviral-naive HIV-1-infected individuals in a midwest university clinicAIDS.  20:2115-2116. 2006
2006 Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapyHIV Medicine.  7:437-441. 2006
2005 Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosisClinical Infectious Diseases.  41:1326-1332. 2005
2005 Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected personsClinical Infectious Diseases.  41:1045-1048. 2005
2005 Antiretroviral resistance among HIV-positive pregnant women who have antiretroviral experience from previous pregnancyAIDS.  19:1439. 2005

Chapter

Year Title Altmetric
2013 Infections of the immunocompromised patient.  704-709. 2013
2012 Infections of the immunocompromised patient.  704-709. 2012
2012 Prevention of hepatitis infection in HIV-Infected patients.  151-161. 2012

Principal Investigator On

  • A-Z Clinical Trials Unit  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2020 - 2027
  • Private Grant  awarded by GlaxoSmithKline 2014 - 2022
  • Private Grant  awarded by Janssen 2020 - 2022
  • Private Grant  awarded by GlaxoSmithKline 2018 - 2022
  • Private Grant  awarded by VIIV HEALTHCARE COMPANY 2016 - 2021
  • AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections [ACTG LOC: PF Chair A5332]  awarded by University of California, Los Angeles 2020 - 2021
  • AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections [ACTG LOC: TSG-Sci Comm] Sub award# 1560 G YB529  awarded by University of California, Los Angeles 2020 - 2021
  • HPTN 083-A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men  awarded by FAMILY HEALTH INTERNATIONAL 2017 - 2021
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2020 - 2021
  • Evaluating Nonavalent HPV vaccine Immunogenicity among Adult Renal Transplant Recipients  awarded by Northwestern University 2016 - 2021
  • High VS. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients  awarded by VANDERBILT UNIVERSITY 2017 - 2021
  • Effect of Pitavastatin on Kidney Function in HIV-infected Persons  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2015 - 2021
  • A5361s: Pitavastatin to Reduce Physical Function Impairment and Frailty in HIV (PREPARE)  awarded by University of California, Los Angeles 2018 - 2021
  • Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)  awarded by University of Colorado 2016 - 2021
  • Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)  awarded by MASSACHUSETTS GENERAL HOSPITAL 2014 - 2021
  • Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332) and ACTG A5333s The Mechanistic Substudy of REPRIEVE  awarded by MASSACHUSETTS GENERAL HOSPITAL 2014 - 2021
  • Private Grant  awarded by GlaxoSmithKline 2019 - 2021
  • Private Grant  awarded by VIIV HEALTHCARE COMPANY 2016 - 2021
  • ACTG Protocol Funds  awarded by University of California, Los Angeles 2018 - 2020
  • Leadership And Operations Center (LOC), AIDS Clinical Trials Group (ACT6) [UM1AI068636]-A5332 Committee Chair Support  awarded by University of California, Los Angeles 2018 - 2020
  • Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG) (UM1A068636-13)  awarded by University of California, Los Angeles 2018 - 2020
  • Alabama Clinical Trials Unit (CTU)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2017 - 2020
  • Private Grant  awarded by BAVARIAN NORDIC A/S 2019 - 2020
  • Private Grant  awarded by Gilead Sciences ^ 2020
  • Cardiovascular Disease Risk in HIV-Infected Women: Sex-Specific Mechanisms of Risk and Risk Reduction Among REPRIEVE Trial Participants  awarded by Brigham and Women's Hospital 2016 - 2020
  • AIDS Clinical Trials Group (ACTG) A5332/A5340 Salary Support  awarded by Brigham and Women's Hospital 2015 - 2019
  • Private Grant  awarded by Gilead Sciences ^ 2019
  • Evaluating Nonavalent HPV Vaccine Immunogenicity among Adult Renal Transplant Recipients (Fixed Price Agreement)  awarded by Northwestern University 2016 - 2019
  • Private Grant  awarded by VIIV HEALTHCARE COMPANY 2016 - 2018
  • AIDS Clinical Trials Group: Protocol Funds FTE Funding  awarded by Brigham and Women's Hospital 2014 - 2018
  • Aids Clinical Trials Group (ACTG) - TSG/Research Science Committee  awarded by Brigham and Women's Hospital 2014 - 2018
  • AIDS Clinical Trials Group: Protocol Funds  awarded by Brigham and Women's Hospital 2014 - 2018
  • A5361s: Pitvastatin to Reduce Physical Function Impairment and Frailty in HIV  awarded by Brigham and Women's Hospital 2016 - 2018
  • Private Grant  awarded by Gilead Sciences ^ 2012 - 2017
  • Private Grant  awarded by Gilead Sciences ^ 2012 - 2017
  • HPTN 083 A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender  awarded by FAMILY HEALTH INTERNATIONAL 2016 - 2017
  • Private Grant  awarded by BAVARIAN NORDIC A/S 2014 - 2017
  • Effect of Low Dose Methotrexate on Endothelial Function and Inflammation in HIV - A5314  awarded by Brigham and Women's Hospital 2013 - 2017
  • Private Grant  awarded by Gilead Sciences ^ 2012 - 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2012 - 2016
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2013 - 2015
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2014 - 2015
  • Private Grant  awarded by BAVARIAN NORDIC A/S 2013 - 2015
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2012 - 2014
  • UAB Center for AIDS Research - The Detrimental Nexus of HCV and HIV Infection on Bioenergetics and Immune Function  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2009 - 2014
  • Private Grant  awarded by Gilead Sciences ^ 2012 - 2014
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2012 - 2014
  • A5280 "A Prospective, Randomized, Double-Blind Phase II Trial of High-Dose Vitamin D and Calcium for Bone Health in HIV-Infected Individuals Initiating Highly Active Antiretroviral Therapy (HAART)"  awarded by Brigham and Women's Hospital 2012 - 2013
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2013
  • Private Grant  awarded by ABBVIE INC 2013
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2011 - 2013
  • A5280 "A Prospective, Randomized, Double-Blind Phase II Trial of High-Dose Vitamin D and Calcium for Bone Health in HIV-Infected Individuals Initiating Highly Active Antiretroviral Therapy (HAART)"  awarded by SOCIAL & SCIENTIFIC SYSTEMS 2011 - 2012
  • Investigator On

  • Determining the Structural- and Functional-Level Effects of Diet-Specific Interventions on the Gut Microbiota of a Racially Diverse Sample of Southern United States Adults  awarded by National Cancer Institute/NIH/DHHS 2020 - 2025
  • UAB Center for AIDS Research (CFAR)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2019 - 2024
  • UAB Center for AIDS Research - Core C - Clinical Core  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2019 - 2024
  • Interdisciplinary Training In Kidney-Related Research  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2019 - 2024
  • Clincial Research Site Activities for the LTE to HVTN 117/HPX2004  awarded by Hutchinson (Fred) Cancer Research Center 2018 - 2023
  • VVTEU Protocol Development and Implementation for Task Areas B-C Phase II Vaccine Trial for Influenza (“Flu Pandemic” or “H7”)  awarded by VANDERBILT UNIVERSITY MEDICAL CENTER 2014 - 2023
  • Vaccine and Treatment Evaluation Units  awarded by VANDERBILT UNIVERSITY MEDICAL CENTER 2014 - 2023
  • Vaccine and Treatment Evaluation Units - Admin Task  awarded by VANDERBILT UNIVERSITY 2014 - 2023
  • Private Grant  awarded by REGENERON PHARMACEUTICALS, INC. 2020 - 2023
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2020 - 2023
  • Kidney Undergraduate Research Experience (KURE)  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2023
  • UAB Institutional Career Development Program in HIV-Related Heart, Lung, Blood and Research  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2018 - 2023
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2020 - 2023
  • Private Grant  awarded by SANOFI PASTEUR LIMITED 2020 - 2022
  • HPX3002/HVTN 706 Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center 2020 - 2022
  • Private Grant  awarded by Gilead Sciences ^ 2016 - 2022
  • CoVPN 3003 Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center 2020 - 2021
  • CoVPN 5001 (Acute Immune Responses to SARS-CoV-2 Infection) Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center 2020 - 2021
  • HVTN 405/HPTN 1901 Protocol Funding (PF) - Birmingham Clinical Research Site  awarded by Hutchinson (Fred) Cancer Research Center 2020 - 2021
  • Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG) COVID 19 SUPPLEMENT  awarded by Emory University 2020 - 2021
  • Unsolicited R24 CFAR Network of Clinical Systems (CNICS)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2016 - 2021
  • The Guts of HIV: Innate Immune Dysregulation as a Central Mechanism of Gastrointestinal and Liver Disease in HIV-1-Infected Individuals  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2015 - 2021
  • Impact of CCR5 Blockade in HIV+Kidney Transplant Recipients  awarded by University of California, San Francisco 2019 - 2021
  • HOPE in Action: A Clinical Trial of HIV-to-HIV Liver Transplantation  awarded by Johns Hopkins University 2019 - 2021
  • Convalescent Plasma Randomized Clinical Trials for SARS-CoV-2 Prophylaxis and Early COVID-19 Treatment are Foundational for Subsequent Hyperimmune Globulin and Vaccines  awarded by Johns Hopkins University 2020 - 2021
  • Neutrophil Dysregulation as a Driving Mechanism of Cardiovascular Disease in HIV-1-Infection  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2016 - 2021
  • Private Grant  awarded by GENECURE BIOTECHNOLOGIES, LLC 2015 - 2021
  • CoVPN 3002 Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center 2020
  • HVTN Protocol Funding Year 14  awarded by Hutchinson (Fred) Cancer Research Center 2019 - 2020
  • HVTN 703/HPTN 081 Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center 2015 - 2020
  • Private Grant  awarded by Gilead Sciences ^ 2018 - 2020
  • (CSSC-001) Convalescent Plasma to Stem Coronavirus: A Randomized Controlled Double Blinded Phase 2 Study Comparing the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. control( SARS-CoV-2 non-immune plasma) among Adults Exposed to COVID-19 and (CSSC-004) Convalescent Plasma to Stem Coronavirus: A Randomized Controlled Double Blinded Phase 2 Study Comparing the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 non-immune plasma)  awarded by Johns Hopkins University 2020
  • HVTN 704/HPTN 085 Protocol Funding (PF) - Birmingham Clinical Research Site  awarded by Hutchinson (Fred) Cancer Research Center 2018 - 2019
  • HVTN Protocol Funding Year 13  awarded by Hutchinson (Fred) Cancer Research Center 2018 - 2019
  • NIAID-Fred Hutch-Janssen Collaboration CTU/Clinical Trial Site Activities for HVTN 118/HPX2003 - Birmingham Clinical Research Site  awarded by Hutchinson (Fred) Cancer Research Center 2018 - 2019
  • Alabama Coalition for Testing, Interventions, and Engagement in Hepatitis C Care (ACTIVE-Care)  awarded by GILEAD FOUNDATION 2015 - 2019
  • UAB Center for Clinical and Translational Science (CCTS) (3 Linked Awards UL1, KL2, TL1)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2015 - 2019
  • COMPLETED - SPORE in Cervical Cancer - Project 3  awarded by Johns Hopkins University 2014 - 2019
  • SPORE in Cervical Cancer  awarded by Johns Hopkins University 2014 - 2019
  • HPTN 078: Enhancing Recruitment, Linkage to Care and Treatment for HIV-Infected Men Who Have Sex with Men (MSM) in the United States  awarded by FAMILY HEALTH INTERNATIONAL 2015 - 2019
  • Private Grant  awarded by PROTEUS DIGITAL HEALTH, INC. 2017 - 2019
  • UAB Center for AIDS Research  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2014 - 2019
  • UAB Center for AIDS Research - Clinical Core C  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2014 - 2019
  • UAB Center for AIDS Research - Lipidomic Profiling in HIV Patients Newly Initiating Antiretroviral Treatment  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2014 - 2019
  • UAB Center for AIDS Research - The Microbiome, Diet, and Incomplete CD4 Recovery on Antiretroviral Therapy  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2014 - 2019
  • UAB Center for AIDS Research - The Role of HIV-Infection and Antiretroviral Therapy Related Mitochondrial Toxicity in Accelerated Aging  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2014 - 2019
  • Private Grant  awarded by JANSSEN R&D IRELAND 2016 - 2019
  • Private Grant  awarded by GlaxoSmithKline 2012 - 2019
  • Private Grant  awarded by Gilead Sciences ^ 2016 - 2019
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2017 - 2019
  • Comprehensive Cancer Center Core Support Grant - Administrative Supplement to Stimulate Research in HIV/AIDS Cancer Research  awarded by National Cancer Institute/NIH/DHHS 2017 - 2019
  • HVTN 704/HPTN 085 Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center 2016 - 2018
  • HVTN Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center 2015 - 2018
  • NIAID-Fred Hutch-Janssen Collaboration CTU/Clinical Trial Site Activities for HVTN 117/118  awarded by Hutchinson (Fred) Cancer Research Center 2015 - 2018
  • Private Grant  awarded by GENOCEA BIOSCIENCES, INC. 2016 - 2018
  • Private Grant  awarded by GENOCEA BIOSCIENCES, INC. 2017 - 2018
  • Private Grant  awarded by VICAL, INC. 2017 - 2018
  • Private Grant  awarded by MERCK & COMPANY, INC. ^ 2015 - 2018
  • Private Grant  awarded by Gilead Sciences ^ 2015 - 2018
  • Alabama Clinical Trials Unit (CTU)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2013 - 2017
  • Private Grant  awarded by ABBVIE INC 2013 - 2017
  • Private Grant  awarded by MERCK & COMPANY, INC. ^ 2014 - 2017
  • Private Grant  awarded by Gilead Sciences ^ 2015 - 2017
  • Private Grant  awarded by GENOCEA BIOSCIENCES, INC. 2015 - 2017
  • Private Grant  awarded by Gilead Sciences ^ 2013 - 2017
  • Private Grant  awarded by Gilead Sciences ^ 2013 - 2017
  • Private Grant  awarded by Gilead Sciences ^ 2014 - 2017
  • UAB-MISS WIHS Cohort  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2013 - 2016
  • Screening, Evaluation, and Treatment of Anal Intraepithelial Neoplasia  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION 2014 - 2016
  • Private Grant  awarded by GENOCEA BIOSCIENCES, INC. 2015 - 2016
  • Private Grant  awarded by CEPHEID 2015 - 2016
  • Alabama Coalition for Testing, Interventions, and Engagement in Hepatitis C Care (ACTIVE-Care)  awarded by GILEAD FOUNDATION 2015 - 2016
  • Private Grant  awarded by GENOCEA BIOSCIENCES, INC. 2014 - 2016
  • Private Grant  awarded by Gilead Sciences ^ 2013 - 2016
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2012 - 2016
  • Private Grant  awarded by HEMISPHERX BIOPHARMA, INC. 2012 - 2016
  • Private Grant  awarded by VICAL, INC. 2014 - 2016
  • Private Grant  awarded by Gilead Sciences ^ 2013 - 2016
  • Private Grant  awarded by GlaxoSmithKline 2015
  • HVTN 703/HPTN 081 Site Readiness  awarded by Hutchinson (Fred) Cancer Research Center 2015
  • HVTN Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center 2014 - 2015
  • Private Grant  awarded by MERCK & COMPANY, INC. ^ 2014 - 2015
  • Regional AIDS Education and Training Centers-Base  awarded by Emory University 2014 - 2015
  • Private Grant  awarded by Gilead Sciences ^ 2013 - 2015
  • Population Genetics Analysis Program: Immunity to Vaccines/Infections II  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2012 - 2015
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2014 - 2015
  • Private Grant  awarded by Gilead Sciences ^ 2014 - 2015
  • Private Grant  awarded by Gilead Sciences ^ 2010 - 2015
  • HVTN Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center 2014
  • Private Grant  awarded by GENOCEA BIOSCIENCES, INC. 2012 - 2014
  • Private Grant  awarded by ABBVIE INC 2013 - 2014
  • Private Grant  awarded by GlaxoSmithKline 2011 - 2014
  • Private Grant  awarded by Gilead Sciences ^ 2012 - 2014
  • UAB Center for AIDS Research  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2009 - 2014
  • Private Grant  awarded by Gilead Sciences ^ 2012 - 2014
  • Private Grant  awarded by GlaxoSmithKline 2010 - 2014
  • Private Grant  awarded by Genentech 2012 - 2014
  • HVTN 505 Protocol Implementation Funds  awarded by Hutchinson (Fred) Cancer Research Center 2010 - 2013
  • HVTN Protocol Implementation Funds  awarded by Hutchinson (Fred) Cancer Research Center 2010 - 2013
  • Private Grant  awarded by Gilead Sciences ^ 2012 - 2013
  • Alabama - Clinical Trials Unit  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2007 - 2013
  • Private Grant  awarded by Gilead Sciences ^ 2013
  • Private Grant  awarded by Gilead Sciences ^ 2012 - 2013
  • Private Grant  awarded by Gilead Sciences ^ 2012 - 2013
  • Education And Training

  • Doctor of Medicine in Internal Medicine Residency Program, University of Tennessee System : Memphis 1999
  • Bachelor of Arts in English / Language Arts Teacher Education, University of Tennessee System : Knoxville 1992
  • UAB Hospital, Internship 2000
  • UAB Hospital, Residency 2002
  • Barnes-Jewish West County Hospital, Postdoctoral Fellowship 2004
  • Full Name

  • Edgar Overton